Discontinued — last reported Q4 '25
Accenture Interest Paid decreased by 92.1% to $9.03M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 47.5%, from $17.19M to $9.03M. Over 3 years (FY 2021 to FY 2024), Interest Paid shows relatively stable performance with a 1.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.03M | $9.03M | $11.49M | $11.49M | $11.49M | $11.49M | $11.63M | $11.63M | $11.63M | $11.63M | $9.30M | $9.30M | $9.30M | $9.30M | $12.58M | $17.19M | $114.98M | $9.03M |
| QoQ Change | — | +0.0% | +27.2% | +0.0% | +0.0% | +0.0% | +1.2% | +0.0% | +0.0% | +0.0% | -20.0% | +0.0% | +0.0% | +0.0% | +35.3% | +36.7% | +568.9% | -92.1% |
| YoY Change | — | — | — | — | +27.2% | +27.2% | +1.2% | +1.2% | +1.2% | +1.2% | -20.0% | -20.0% | -20.0% | -20.0% | +35.3% | +84.9% | +814.1% | -47.5% |